KR20210097160A - 여포성 림프종의 치료 방법 - Google Patents

여포성 림프종의 치료 방법 Download PDF

Info

Publication number
KR20210097160A
KR20210097160A KR1020217020004A KR20217020004A KR20210097160A KR 20210097160 A KR20210097160 A KR 20210097160A KR 1020217020004 A KR1020217020004 A KR 1020217020004A KR 20217020004 A KR20217020004 A KR 20217020004A KR 20210097160 A KR20210097160 A KR 20210097160A
Authority
KR
South Korea
Prior art keywords
subject
ibrutinib
mutations
genes
atp6ap1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020217020004A
Other languages
English (en)
Korean (ko)
Inventor
스리람 발라수브라마니안
Original Assignee
얀센 바이오테크 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 바이오테크 인코포레이티드 filed Critical 얀센 바이오테크 인코포레이티드
Publication of KR20210097160A publication Critical patent/KR20210097160A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020217020004A 2018-11-30 2019-11-26 여포성 림프종의 치료 방법 Withdrawn KR20210097160A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862773678P 2018-11-30 2018-11-30
US62/773,678 2018-11-30
PCT/US2019/063234 WO2020112761A1 (en) 2018-11-30 2019-11-26 Methods of treating follicular lymphoma

Publications (1)

Publication Number Publication Date
KR20210097160A true KR20210097160A (ko) 2021-08-06

Family

ID=68966021

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217020004A Withdrawn KR20210097160A (ko) 2018-11-30 2019-11-26 여포성 림프종의 치료 방법

Country Status (16)

Country Link
US (1) US20200171034A1 (https=)
EP (1) EP3886992A1 (https=)
JP (1) JP2022513666A (https=)
KR (1) KR20210097160A (https=)
CN (1) CN113164782A (https=)
AU (1) AU2019388899A1 (https=)
BR (1) BR112021009978A2 (https=)
CA (1) CA3120960A1 (https=)
EA (1) EA202191509A1 (https=)
IL (1) IL283365A (https=)
JO (1) JOP20210126A1 (https=)
MA (1) MA54292A (https=)
MX (1) MX2021006368A (https=)
PH (1) PH12021551140A1 (https=)
SG (1) SG11202105309YA (https=)
WO (1) WO2020112761A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2983670A4 (en) * 2013-04-08 2017-03-08 Pharmacyclics LLC Ibrutinib combination therapy
CA2914284A1 (en) * 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US20160032404A1 (en) * 2014-08-01 2016-02-04 Pharmacyclics Llc Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor
CA2980393A1 (en) * 2015-03-18 2016-09-22 Memorial Sloan Kettering Cancer Center Methods for diagnosing and treating follicular lymphoma
HK1250925A1 (zh) * 2015-04-06 2019-01-18 Janssen Pharmaceutica, N.V. 包含依鲁替尼的组合物
WO2017087947A2 (en) * 2015-11-19 2017-05-26 Pharmacyclics Llc Method of treatment of follicular lymphoma with a btk inhibitor
PH12021551936A1 (en) * 2019-02-15 2022-05-23 Janssen Biotech Inc Combination therapy for treatment of b-cell malignancies

Also Published As

Publication number Publication date
CN113164782A (zh) 2021-07-23
JOP20210126A1 (ar) 2019-11-26
SG11202105309YA (en) 2021-06-29
EP3886992A1 (en) 2021-10-06
US20200171034A1 (en) 2020-06-04
JP2022513666A (ja) 2022-02-09
EA202191509A1 (ru) 2021-10-26
BR112021009978A2 (pt) 2021-08-17
WO2020112761A1 (en) 2020-06-04
MA54292A (fr) 2021-10-06
PH12021551140A1 (en) 2021-10-25
AU2019388899A1 (en) 2021-06-10
IL283365A (en) 2021-07-29
MX2021006368A (es) 2021-10-13
CA3120960A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
Spina et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma
Singh et al. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas
EP3077001B1 (en) Methods to distinguish waldenström's macroglobulinemia from igm monoclonal gammopathy of undetermined significance
CA3109391A1 (en) Methods related to bronchial premalignant lesion severity and progression
Leprieur et al. Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression
Pyo et al. Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer
AU2016308057A1 (en) Biomarkers for treatment of alopecia areata
Visconte et al. Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts
Berti et al. EBV-induced lymphoproliferative disorders in rheumatic patients: a systematic review of the literature
EP2855516B1 (en) Inflammation-enabling polypeptides and uses thereof
US20150133390A1 (en) Identification of New Therapeutic Uses for Known Therapeutic Agents
Ruan Molecular profiling and management of mantle cell lymphoma
WO2020256868A1 (en) Immune system modulators for the treatment of squamous lung premalignancy
Sivanand et al. The neoantigen landscape of mycosis fungoides
KR20210097160A (ko) 여포성 림프종의 치료 방법
US20240102081A1 (en) Identifying disease-causing human ddx41 genetic variants
Pagadala Using Germline Variation to Study Inter-Individual Variability in Cancer Risk and Host Anti-Tumor Immune Response
Gitelman Molecular incompatibility as a determinant of antibody-mediated rejection following kidney transplantation
EP4561592A2 (en) Assessing and treating mesothelioma
Gunduz et al. P2. 01-57 New Prognostic Markers in Patients with Lung Cancer Treated with Immunoterapy: NLR and PLR
Shackleton Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling
WO2024227553A1 (en) Biomarkers for use in cancer treatment and predicting responsiveness to a cancer therapy
Saunthararajah Splicing factor 3b subunit 1 (Sf3b I) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts
Teixeira Splenic marginal zone lymphoma: a review of the clinical presentation, pathology, molecular biology, and management
CABAU et al. SERUM METABOLOMICS REVEALS DYSLIPIDAEMIA IN GOUT AND HYPERURICEMIA: EXPLORING INFLAMMATORY LINKS THROUGH INTEGRATIVE MULTI-OMICS

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202